What do systematic reviews say?

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 147 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 208 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1250 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1099 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 295 participants
  Very low

Intervention not reported

The review found no eligible studies for this question.

• Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children 2022 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 127 participants
  High

Intervention not reported

• Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children 2022 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 120 participants
  Moderate

Intervention not reported

• Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children 2022 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 200 participants
  Moderate

Intervention not reported

• Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 46 participants
  Very low

Intervention not reported

The review found no eligible studies for this question.

• Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 3 participants
  Very low

Summary of findings table ‐ Cannabis vs placebo

Summary of findings table ‐ Cannabis probably leads to higher spasticity: number of participants reporting reduction of 30% in the… compared with placebo (moderate certainty).

• Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis 2022 · Cochrane Headline outcomes only
  OR 2.51 [1.56, 4.04]
  5 studies · 1143 participants
  Moderate

Summary of findings table ‐ Cannabis vs placebo

It is very uncertain whether summary of findings table ‐ Cannabis changes pain:number of participants reporting pain relief of 50% or greater… compared with placebo (very low certainty).

• Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis 2022 · Cochrane Headline outcomes only
  OR 4.23 [1.11, 16.17]
  1 study · 48 participants
  Very low

Summary of findings table ‐ Cannabis vs placebo

Summary of findings table ‐ Cannabis probably leads to higher PGIC:number of participants reporting much or very much improvement… compared with placebo (moderate certainty).

• Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis 2022 · Cochrane Headline outcomes only
  OR 1.8 [1.37, 2.36]
  8 studies · 1215 participants
  Moderate

Summary of findings table ‐ Cannabis vs placebo

• Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 1942 participants
  Low

Summary of findings table ‐ Cannabis vs placebo

Summary of findings table ‐ Cannabis may leads to higher withdrawn due to adverse events ( compared with placebo (low certainty).

• Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis 2022 · Cochrane Headline outcomes only
  OR 2.41 [1.51, 3.84]
  21 studies · 3110 participants
  Low

Summary of findings table ‐ Cannabis vs placebo

Summary of findings table ‐ Cannabis showed no clear difference in SAEs: number of participants with SAEs ( compared with placebo (low certainty).

• Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis 2022 · Cochrane Headline outcomes only
  OR 1.38 [0.96, 1.99]
  20 studies · 3124 participants
  Low

Summary of findings table ‐ Cannabis vs placebo

Summary of findings table ‐ Cannabis may leads to higher specific AEs:number of participants reporting nervous system… compared with placebo (low certainty).

• Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis 2022 · Cochrane Headline outcomes only
  OR 2.61 [1.53, 4.44]
  7 studies · 1154 participants
  Low

Summary of findings table ‐ Cannabis vs placebo

Summary of findings table ‐ Cannabis may leads to higher specific AEs: number of participants reporting psychiatric disorders ( compared with placebo (low certainty).

• Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis 2022 · Cochrane Headline outcomes only
  OR 1.94 [1.31, 2.88]
  6 studies · 1122 participants
  Low